Prediction of human pharmacokinetics - Evaluation of methods for prediction of hepatic metabolic clearance

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 803-828

  Fagerholm, Urban ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LIDOCAINE; LIVER ENZYME; PROPRANOLOL; VERAPAMIL; WARFARIN; XENOBIOTIC AGENT;

ALLOMETRY; ARTICLE; BLOOD FLOW VELOCITY; BODY WEIGHT; CELL ACTIVITY; CELL CULTURE; CELL FRACTIONATION; CELL ISOLATION; COMPUTER MODEL; CONTROLLED STUDY; CRYOPRESERVATION; DRUG BINDING; DRUG ISOLATION; DRUG METABOLISM; DRUG PENETRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER CLEARANCE; LIVER METABOLISM; MICROSOME; NONHUMAN; SPECIES DIFFERENCE;

EID: 34447312263     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.6.0007     Document Type: Article

References (316)

1. Adolph, E. F. (1949) Quantitative relations in the physiological contributions of mammals. Science 109: 579-85
2. Ahmad, A. B., Bennett, P. N., Rowland, M. (1983) Models of hepatic drug clearance: discrimination between the 'well-stirred' and 'parallel-tube' models. J. Pharm. Pharmacol. 35: 219-224
3. Andersson, T. B., Sjöberg, H., Hoffmann, K.-J., Boobis, A. R., Watts, P., Edwards, R. J., Lake, B. G., Price, R. J., Renwick, A. B., Gómez-Lechón, M. J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Goldfarb, P. S., Lewis, D. F. V., Corcos, L. Guillouzo, A., Taavitsainin, P., Pelkonen, O. (2001) An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab. Dispos. 29: 712-720
4. Andersson, T. B., Bredberg, E., Ericsson, H., Sjöberg, H. (2004) An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab. Dispos. 32: 715-721
5. Anissimov, Y. G., Roberts, M. S. (2002) A compartmental model of hepatic disposition kinetics: 1. Model development and application to linear kinetics. J. Pharmacokinet.. Pharmacodyn. 29: 131-156
6. Anissimov, Y. G., Bracken, A. J., Roberts, M. S. (1999) Interconnected-tubes model of hepatic elimination: Steady-state considerations. J. Theor. Biol. 199: 435-447
7. Ashforth, E. I., Carlile, D. J., Chenery, R., Houston, J. B. (1995) Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J. Pharmacol. Exp. Ther. 274: 761-766
8. Austin, R. P., Barton, P., Cockcroft, S. L., Wenlock, M. C., Riley, R. J. (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties. Drug Metab. Dispos. 30: 1497-1503
9. Austin, R. P., Barton, P., Mohmed, S., Riley, R. J. (2005) The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. 33: 419-425
10. Bäärnhielm, C., Dahlbäck, H., Skånberg, I. (1986) In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol. Toxicol. 59: 113-122
11. Bachmann, K. (1989) Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J. Applied Toxicol. 9: 331-338
12. Bachmann, K., Byers, J., Ghosh, R. (2003) Prediction of in vivo clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica 33: 475-483
13. Bae, S. K., Lee, S. J., Kim, Y. G., Kim, S. H., Kim, J. W., Kim, T., Lee, M. G. (2005) Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Dispos. 26: 99-115
14. Balakin, K. V., Ekins, S., Bugrim, A., Ivanenkov, Y. A., Korolev, D., Nikolsky, Y. V., Ivashchenko, A. A., Savchuk, N. P., Nikolskaya, T. (2004) Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates. Drug Metab. Dispos. 32: 1111-1120
15. Balon, K., Riebesehl, B. U., Muller, B. W. (1999) Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res. 16: 882-888
16. Bayliss, M. K., Bell, J. A., Jenner, W. N., Park, G. R., Wilson, K. (1999) Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29: 253-268
17. Benedict, F. G. (1938) Vita energetics: a study in comparative basal metabolism. Carnegie Inst. Publ. 503: 1-215
18. Björkman, S., Redke, F. (2000) Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man. J. Pharm. Pharmacol. 52: 1065-1074
19. Blanchard, N., Richert, L. Notter, B., Delobel, F., David, P., Coassolo, P., Lavé, T. (2004) Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur. J. Pharm. Sci. 23: 189-199
20. Blanchard, N., Alexandre, E., Abadie, C., Lavé, T., Heyd, B., Mantion, G., Jaeck, D., Richert, L., Coassolo, P. (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35: 1-15
21. Blanchard, N., Hewitt, N., Silber, P., Jones, H. Coassolo, P., Lavé, T. (2006) Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. J. Pharm. Pharmacol. 58: 633-641
22. Blom, A., Scaf, A. H. J., Meijer, D. K. F. (1982) Hepatic drug transport in the rat: A comparison between isolated hepatocytes, the isolated perfused liver and the liver in vivo. Biochem. Pharmacol. 31: 1553-1565
23. Blouin, A. (1977) Morphometry of liver sinusoidal cells. In: Wisse, E., Knook, D. L. (eds) Kupffer cells and other liver sinusoidal cells. Elsevier/North-Holland Biomedical Press, New York
24. Bogaards, J. J. P., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., Walther, B. (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30: 1131-1152
25. Bonate, P. L., Howard, D. (2000) Critique of prospective allometric scaling: Does the emperor have clothes? J. Clin. Pharmacol. 40: 335-340
26. Bonati, M., Latinit, A., Tognoni, G., Young, J. F., Garattini, S. (1984) Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Met. Rev. 15: 1355-1383
27. Boobis, A., Gundert-Remy, U., Kremers, P., Macheras, P., Pelkonen, O. (2002) In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organized by COST B15. Eur. J. Pharm. Sci. 17: 183-193
28. Boxenbaum, H. (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm. 8: 165-176
29. Boxenbaum, H. (1982) Interspecies scaling, allometry, physiological time, and ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10: 201-227
30. Boxenbaum, H., Fertig, J. B. (1984) Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur. J. Drug Metab. Pharmacokinet. 9: 177-183
31. Boxenbaum, H., Ronfeld, R. (1983) Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. R768-774
32. Brandon, E., Raap, C., Meijerman, I., Beijnen, J., Schellens, J. (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 189: 233-246
33. Brody, S. (1937) Relativity of physiologic time and physiologic weight. Growth 1: 60-67
34. Brody, S. (1945) In: Bioenergetics and growth with special reference to the efficiency complex in domestic animals. Reinhold, New York
35. Bugrim, A., Nikolskaya, T., Nikolsky, Y. (2004) Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Disc. Today 9: 127-135
36. Caldwell, J. (1981) The current status of attempts to predict species differences in drug metabolism. Drug Metab. Rev. 12: 221-237
37. ss and t 1/2 be predicted from in-vivo rat data? Eur. J. Drug Metab. Pharmacokinet. 29: 133-143
38. Campbell, B. (1994) Can allometric interspecies scaling be used to predict human kinetics? Drug Inf. J. 28: 235-245
39. Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H.-C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., Sun, D. (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model? Pharm. Res. 23: 1675-1686
40. Carlile, D. J., Stevens, A. J., Ashforth, E. I. L, Waghela, D., Houston, J. B. (1998) In vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Drug Metab. Dispos. 26: 216-221
41. Carlile, D. J., Hakooz, N., Bayliss, M. K., Houston, J. B. (1999a) Microsomal prediction of in vivo clearance of CYP2C9 substrates. Br. J. Clin. Pharmacol. 47: 625-635
42. Carlile, D. J., Hakooz, N., Houston, J. B. (1999b) Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity. Drug Metab. Dispos. 27: 526-532
43. Carrel, A. (1931) Physiological time. Science 74: 618-621
44. Chandra, P., Brouwer, K. L. R. (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21: 719-735
45. Chiba, M., Fujita, S., Suzuki, T. (1990) Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J. Pharm. Sci. 79: 281-287
46. Chiou, W. L. (1984) A new model-independent physiological approach to study hepatic drug clearance and its applications. Int. J. Clin. Pharmacol. Ther. Toxicol. 22: 577-590
47. Chiou, W. L., Barve, A. (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15: 1792-1795
48. Chiou, W. L., Buehler, P. W. (2002) Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm. Res. 19: 868-874
49. Chiou, W. L., Choi, Y. M. (1995) Unbound total (plasma) clearance approach in interspecies pharmacokinetics correlation: theophylline-cimetidine interaction. Pharm. Res. 12: 1238-1239
50. Chiou, W. L., Hsu, F. H. (1988) Correlation between unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharm. Res. 5: 668-672
51. Chiou, W. L., Robbie, G., Chung, S. M., Wu, T. C., Ma, C. (1998) Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm. Res. 15: 1474-1479
52. Chiou, W. L., Jeong, H. Y., Chung, S. M., Wu, T. C. (2000) Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res. 17: 135-140
53. Chow, F. S., Piekoszewski, W., Jusko, W. J. (1997) Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab. Dispos. 25: 610-616
54. Chung, M., Radwanski, E., Loenberg, D., Lin, C., Oden, E., Symchowicz, S., Gural, R. P., Miller, G. H. (1985) Interspecies pharmacokinetic scaling of SCH34343. J. Antimicrob. Chemother. 15: 227-233
55. Clarke, S. E., Jeffrey, P. (2001) Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 31: 591-598
56. Crivori, P., Zamora, I., Speed, B., Orrenius, C., Poggesi, I. (2004) Model based on GRID-derived descriptors for estimating CYP450 enzyme stability of potential drug candidates. J Comput. Aided Mol. Design 18: 155-166
57. Cross, D. M., Bayliss, M. K. (2000) A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metab. Rev. 32: 219-240
58. Cruze, C. A., Kelm, G. R., Meredith, M. P. (1995) Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm. Res. 12: 895-901
59. Davidson, I. W. F., Parker, J. C., Beliles, R. P. (1986) Biological basis for extrapolation across mammalian species. Reg. Toxicol. Pharmacol. 6: 211-237
60. Davies, B., Morris, T. (1993) Physiological parameters in laboratory animals and humans. Pharm. Res. 10: 1093-1099
61. Davis, A. M., Riley, R. J. (2004) Predictive ADMET studies, the challenges and the opportunities. Curr. Opin. Chem. Biol. 8: 378-386
62. De Graaf, I. A. M., van Meijeren, C. E., Pektas, F., Koster, H. J. (2002) Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism. Drug Metab. Dispos. 30: 1129-1136
63. De Kanter, R., Monshouwer, M., Draaisma, A. L., De Jager, M. H., De Graaf, A. M., Proost, J. H., Meijer, D. K. F., Groothuis, G. M. M. (2004) Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon. Xenobiotica 34: 229-241
64. De Loecker, W., Koptelov, V. A., Grischenko, V. I., De Loecker, P. (1998) Effects of cell concentration on viability and metabolic activity during cryopreservation. Cryobiology 37: 103-109
65. Dedrick, R. L. (1973) Animal scale-up. J. Pharmacokinet. Biopharm. 1: 435-461
66. Dedrick, R. L., Bischoff, K. B., Zaharko, D. S. (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother. Rep. Part I 54: 95-101
67. Donato, M. T., Castell, J. V. (2003) Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism. Clin. Pharmacokinet. 42: 153-178
68. Donato, M. T., Gómez-Lechón, M. J., Castell, J. V. (1993) A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal. Biochem. 213: 29-33
69. Ekins, S. (2003) In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem. Soc. Transact. 31: 611-614
70. Ekins, S., Obach, S. R. (2000) Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. J. Pharmacol. Exp. Ther. 295: 463-473
71. Ekins, S., Rose, J. (2002) In silico ADME/Tox: The state of the art. J. Mol. Graph. Mod. 20: 305-309
72. Ekins, S., Murray, G. I., Burke, M. D., Williams, J. A., Marchant, N. C., Hawksworth, G. M. (1995) Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. Drug Metab. Dispos. 23: 1274-1279
73. Ekins, S., Waller, C. L., Swaan, P. W., Cruciani, G., Wrighton, S. A., Wikel, J. H. (2000) Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods 44: 251-272
74. Ekins, S., Boulanger, B., Swaan, P. W., Hupcey, M. A. Z. (2002) Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Design 16: 381-401
75. Ekins, S., Stresser, D. M., Williams, J. A. (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 24: 161-166
76. Ethell, B. T., Ekins, S., Wang, J., Burchell, B. (2002) Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab. Dispos. 30: 734-738
77. Evans, A. M., Hussein, Z., Rowland, M. (1993) Influence on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: analysis by the impulse-response technique and the dispersion model. J. Pharm. Sci. 82: 421-428
78. Fabre, G., Combalbert, J., Berger, Y., Cano, J.-P. (1990) Human hepatocytes as a key in vitro model to improve preclinical drug development. Eur. J. Drug Metab. Pharmacokinet. 15: 165-171
79. Fagerholm, U., Björnsson, M. A. (2005) Clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donator (CINOD) AZD3582. J. Pharm. Pharmacol. 57: 1539-1554
80. FDA. Guidance for industry and reviewers. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers (Draft). http://www.fda.gov/cder/guidance/3814d.ft.pdf
81. Feng, M. R., Lou, X., Brown, R. R., Hutchaleelaha, A. (2000) Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm. Res. 17: 410-418
82. Fischer, R. (1966) In: Fraser, J. T. (ed.) The voices of time. George Braziller, New York, pp 357-382
83. Floby, E., Briem, S., Terelius, Y., Sohlenius-Sternbeck, A.-K. (2004) Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations. Xenobiotica 34: 949-959
84. Forker, E. L., Luxon, B. A. (1982) Hepatic transport kinetics: effect of anatomic and metabolic heterogenecity on estimates of the average transfer coefficients. Am. J. Physiol. 243: G532-540
85. Gagner Milchert, I., Gabrielsson, J., Linde, J., Terelius, Y. (1998) In vitro-in vivo extrapolation of robalzotan metabolic parameters: an interspecies comparison. Eur. Neuropsychopharmacol. 8: 184-185
86. Galetin, A., Brown, C., Hallifax, D., Ito, K., Houston, J. B. (2004) Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Dispos. 32: 1411-1420
87. Gascon, A. R., Calvo, B., Hernandez, R. M., Dominguez-Gil, A., Pedraz, J. L. (1994) Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. Pharm. Res. 11: 945-950
88. Gebhardt, R. (1992) Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol. Ther. 53: 275-354
89. Glaeser, H., Drescher, S., Hofmann, U., Heinkele, G., Somogyi, A. A., Eichelbaum, M., Fromm, M. F. (2004) Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin. Pharmacol. Ther. 76: 230-238
90. Gobburu, J. V. S., Shelver, W. H. (1995) Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. J. Pharm. Sci. 84: 862-865
91. Gómez-Lechón, M. J., Donato, M. T., Castell, J. V., Jover, R. (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 4: 292-312
92. Gómez-Lechón, M. J., Donato, M. T., Castell, J. V., Jover, R. (2004) Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. 5: 443-462
93. th edn, int. edn, McGraw-Hill
94. Goresky, C. A., Pang, K. S., Schwab, A. J., Barker III, F., Cherry, W. F., Bach, G. G. (1992) Uptake of a protein-bound polar compound, acetaminophen sulphate, by perfused rat liver. Hepatology 16: 173-190
95. Goresky, C. A., Bach, G. G., Simard, A., Schwab, A. J., Bracht, A. (2000) Uptake of lactate by the liver: effect of red blood cell carriage. Am. J. Physiol. Gastroint. Liver Physiol. 278: G775-788
96. Grene-Lerouge, N., Bazin-Redureau, M., Debray, M., Scherrmann, J. (1996) Interspecies scaling of clearance and volume of distribution for digoxin-specific fab. Toxicol. Appl. Pharmacol. 138: 84-89
97. Griffin, S. J., Houston, J. B. (2004) Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab. Dispos. 32: 552-558
98. Griffin, S. J., Houston, J. B. (2005) Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspension and monolayer cultures. Drug Metab. Dispos. 33: 115-120
99. Grime, K., Riley, R. J. (2006) The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 7: 251-264
100. Groothuis, G. M., Meijer, D. K. (1996) Drug traffic in the hepatobiliary system. J. Hepatol. 24: 3-28
101. Günter, B. (1975) On theories of biological similarity. In: Beier, W. (Hrsg.) Fortschritte der experimentellen und theoretischen biophysic. Bd. 19. Edition Leipzig, Leipzig
102. Haddad, S., Funk, C. (2001) A novel liver PBPK model as tool for in vitro-in vivo extrapolations. Drug Metab. Rev. 33(Suppl. 1): 204
103. Haenen, B., Rompelberg, C., van Twillert, K., Hamzink, M., Dormans, J., van Eijkeren, J. (2002) Utility of rat liver slices to estimate rat hepatic clearance for application in physiologically based pharmacokinetic modeling: A study with tolbutamide, a compound with low extraction efficiency. Drug Metab. Dispos. 30: 307-313
104. Hakooz, N., Ito, K., Rawden, H., Gill, H., Lemmers, L., Boobis, A. R., Edwards, R. J., Carlile, D. J., Lake, B. G., Houston, J. B. (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm. Res. 23: 533-539
105. Hallifax, D., Rawden, H. C., Hakooz, N., Houston, J. B. (2005) Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab. Dispos. 33: 1852-1858
106. Hansch, C., Leo, A., Mekapati, S. B., Kurup, A. (2004) QSAR and ADME. Bioorg. Med. Chem. 12: 3391-3400
107. Hayes, K. A., Brennan, B., Chenery, R., Houston, J. B. (1995) In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab. Dispos. 23: 349-353
108. Hayssen, V., Lacy, R. C. (1985) Basal metabolic rates in mammals: taxonomic differences in the allometry of BMR and body mass. Comp. Biochem. Physiol. 81: 741-754
109. Hayton, W. L. (1989) Pharmacokinetic parameters for interspecies scaling using allometric techniques. Hlth. Phys. 57 (Suppl. 1): 159-164
110. Henderson, A. J., Guzzo, P. R. (2004) Metabolism-driven optimization of pharmacokinetics. Curr. Drug Disc. May: 17-22
111. Hengstler, J. G., Utesch, D., Steinberg, P., Platt, K. L., Diener, B., Ringel, M., Swales, N., Fischer, T., Biefang, K., Gerl, M., Bottger, T., Oesch, F. (2000) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab. Rev. 32: 81-118
112. Hewitt, N. J., Bühring, K.-U., Dasenbrock, J., Haunschild, J., Ladstetter, B., Utesch, D. (2001) Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab. Dispos. 29: 1042-1050
113. Hinderling, P. H., Dilea, C., Koziol, T., Millington, G. (1993) Comparative kinetics of sematilide in four species. Drug Metab. Dispos. 21: 662-669
114. Hirota, N., Ito, K., Iwatsubo, T., Green, C. E., Tyson, C. A., Shimada, N., Suzuki, H., Sugiyama, Y. (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm. Drug Dispos. 22: 53-71
115. Hoener, B.-A. (1994) Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Dispos. 15: 295-304
116. Houle, R., Raoul, J., Lévesque, J.-F., Pang, K. S., Nicoll-Griffith, D. A., Silva, J. M. (2003) Retention of transporter activities in cryopreserved, isolated rat hepatocytes. Drug Metab. Dispos. 31: 447-451
117. Houston, J. B. (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47: 1469-1479
118. Houston, J. B., Carlile, D. J. (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. 29: 891-922
119. Hu, T.-M., Hayton, W. L. (2001) Allometric scaling of xenobiotic clearance: uncertainty and universality. AAPS Pharm. Sci. 3: article 29
120. Hung, D. Y., Mellick, G. D., Anissimov, Y. G., Weiss, M., Roberts, M. S. (1998) Hepatic structure-pharmacokinetic relationships: The hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. Br. J. Pharmacol. 124: 1475-1483
121. Hung, D. Y., Chang, P, Weiss, M., Roberts, M. S. (2001) Structure-hepatic disposition relationship for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. J. Pharmacol. Exp. Ther. 297: 780-789
122. Hung, D. Y., Siebert, G. A., Chang, P., Anissimov, Y. G., Roberts, M. S. (2004) Disposition kinetics of propranolol isomers in the perfused rat liver. J. Pharmacol. Exp. Ther. 311: 822-829
123. Hussain, A. S., Johnson, R. D., Vachharajani, N. N., Ritschel, W. A. (1993a) Feasibility of developing a neural network for prediction of human pharmacokinetic parameters from animal data. Pharm. Res. 10: 466-469
124. Hussein, Z., Evans, A. M., Rowland, M. (1993b) Physiological models of hepatic drug clearance: Influence of altered protein binding on the elimination of diclofenac in the isolated perfused rat liver. J. Pharm. Sci. 82: 880-885
125. Igari, Y., Sugiyama, Y., Sawada, Y., Iga, T., Hanano, M. (1984) In vitro and in vivo assessment of hepatic and extrahepatic metabolism of diazepam in the rat. J. Pharm. Sci. 73: 826-828
126. Ings, R. M. (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20: 1201-1231
127. Ito, K., Houston, J. B. (2004) Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 21: 785-792
128. Ito, K., Houston, J. B. (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 22: 103-112
129. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., Sugiyama, Y. (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38: 461-499
130. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki H., Sugiyama Y. (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Disp. 17: 273-310
131. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., Sugiyama, Y. (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73: 147-171
132. Izumi, T., Hosiyama, K., Enomoto, S., Sasahara, K., Sugiyama, Y. (1997) Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J. Pharmacol. Exp. Ther. 280: 1392-1400
133. Jansen, J. A. (1981) Influence of plasma protein binding kinetics on hepatic clearance assessed from a "tube" model and a "well-stirred" model. J. Pharmacokinet. Biopharm. 9: 15-26
134. Jezequel, S. G. (1994) Fluconazole: Interspecies scaling and allometric relationships of pharmacokinetic properties. J. Pharm. Pharmacol. 46: 196-199
135. Jolivette, L. J., Ward, K. W. (2005) Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: molecular properties associated with extrapolative success or failure. J. Pharm. Sci. 94: 1467-1483
136. Kansy, M., Senner, F., Gubernator, K. (1998) Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41: 1007-1010
137. Kern, A., Bader, A., Pichlmayr, R., Sewing, K.-F. (1997) Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem. Pharmacol. 54: 761-772
138. Kimura, T., Iwasaki, N., Yokoe, J.-I., Haruta, S., Yokoo, Y., Ogawara, K.-I., Higaki, K. (2000) Analysis and prediction of absorption profile including hepatic first-pass metabolism of N-methyltyramine, a potent stimulant of gastrin release present in beer, after oral ingestion in rats by gastrointestinal-transit-absorption model. Drug Metab. Dispos. 28: 577-581
139. Kleiber, M. (1932) Body size and metabolism. Hilgardia 6: 315-332
140. Kleiber, M. (1961) In: The fire of life: an introduction to animal energetics. Wiley, New York
141. Kleiber, M. (1975) Metabolic turnover rate: A physiological meaning of the metabolic rate per unit body weight. J. Theor. Biol. 53: 199-204
142. Klotz, U., Antonin, K.-H., Beck, P. R. (1976) Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J. Pharmacol. Exp. Ther. 199: 67-73
143. Kono, Y., Yang, S., Roberts, E. A. (1997) Extended primary culture of human hepatocytes in a collagen gel sandwich system. In Vitro Cell. Dev. Biol. Anim. 33: 467-472
144. Krasovskij, G. N. (1976) Extrapolation of experimental data from animals to man. Environ. Health Prespect. 13: 51-58
145. Kroemer, H. K., Echizen, H., Heidemann, H., Eichelbaum, M. (1992) Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260: 1052-1057
146. Kumar, S., Samuel, K., Subramanian, R., Braun, M. P., Stearns, R. A., Chiu, S. H., Evans, D. C., Baillie, T. A. (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J. Pharmacol. Exp. Ther. 303: 969-978
147. Kwon, Y., Morris, M. E. (1997a) Membrane transport in hepatic clearance of drugs I: Extended hepatic clearance models incorporating concentration- dependent transport and elimination processes. Pharm. Res. 14: 774-779
148. Kwon, Y., Morris, M. E. (1997b) Membrane transport in hepatic clearance of drugs II: Zonal distribution patterns of concentration-dependent transport and elimination processes. Pharm. Res. 14: 780-785
149. Lam, J. L., Benet, L. Z. (2004) Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes vs microsomes. Drug Metab. Dispos. 32: 1311-1316
150. Lapka, R., Rejholec, V., Sechser, T., Peterkova, M., Smid M. (1989) Interspecies pharmacokinetic scaling of metazosin, a novel alpha-adrenergic antagonist. Biopharm. Drug Dispos. 10: 581-589
151. Lau, Y. Y., Sapidou, E., Cui, X., White, R. E., Cheng, K.-C. (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab. Dispos. 30: 1446-1454
152. Lavé, T., Coassolo, P. (1998) Commentary on "Integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: Some suggestions". J. Pharm. Sci. 87: 530
153. Lavé, T., Levet-Trafit, B., Schmitt-Hoffmann, A. H., Morgenroth, B., Richter, W,, Chou, R. C. (1995a) Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J. Pharm. Sci. 84: 1285-1290
154. Lavé, T., Schmitt-Hoffmann, A. H., Coassolo, P., Valles, B., Ubeaud, G., Ba, B., Brandt, R., Chou, R. C. (1995b) A new extrapolation method from animals to man: application to a metabolized compound, mofarotene. Life Sci. 56: 473-478
155. Lavé, T., Dupin, S., Schmitt, M., Kapps, M., Meyer, J., Morgenroth, B., Chou, R. C., Jaeck, D., Coassolo P. (1996a) Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26: 839-851
156. Lavé, T., Coassolo, P., Ubeaud, G., Brandt, R., Schmitt, C., Dupin, S., Jaeck, D., Chou, R. C. (1996b) Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharm. Res. 13: 97-101
157. Lavé, T., Saner, A., Coassolo, P., Brandt, R., Schmitt-Hoffmann, A. H., Chou, R. C. (1996c) Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J. Pharm. Pharmacol. 48: 573-577
158. Lavé, T., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., Coassolo, P. (1997a) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci. 86: 584-590
159. Lavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., Coassolo, P. (1997b) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. 14: 152-155
160. Lavé, T., Coassolo, P., Reigner, B. (1999a) Prediction of hepatic metabolic clearance based on interspecies scaling techniques and in vitro-in vivo correlations. Clin. Pharmacokinet. 36: 211-231
161. Lavé, T., Portmann, R., Schenker, G., Gianni, A., Guenzi, A., Girometta, M.-A., Schmitt, M. (1999b) Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 51: 85-91
162. Le Vee, M., Jigorel, E., Glaise, D., Gripon, P., Guguen-Guillouzo, C., Fardel, O. (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci. 28: 109-117
163. LeCluyse, E. L., Bullock, P. L., Parkinson, A. (1996) Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Adv. Drug Del. Rev. 22: 133-186
164. Lee, H. L., Chiou, W. L. (1989a) Erythrocytes as barriers for drug elimination in the isolated liver: I. Doxorubicin. Pharm. Res. 6: 833-839
165. Lee, H. L., Chiou, W. L. (1989b) Erythrocytes as barriers for drug elimination in the isolated liver: II. Propranolol. Pharm. Res. 6: 840-843
166. Leggett, R. W., Williams, L. R. (1995) A proposed blood circulation model for reference man. Health Physics 69: 187-201
167. Lennernäs, H. (1997) Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 49: 627-638
168. Lepist, E.-L, Jusko, W. J. (2004) Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J. Vet. Pharmacol. Ther. 27: 211-218
169. Lester, D., Keokosky, W. Z. (1967) Alcohol metabolism in the horse. Life Sci. 6: 2313-2319
170. Li, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E., Silber, P. M. (1999) Cryopreserved human hepatocytes: characterization of drug-metabolising enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability and drug-drug interaction potential. Chem. Biol. Interact. 121: 17-35
171. Lin, J. H. (1995) Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23: 1008-1021
172. Lin, J. H., Hayashi, M., Awazu, S., Hanano, M. (1978) Correlation between in vitro and in vivo drug metabolism rate: oxidation of ethoxybenzamide in rat. J. Pharmacokinet. Biopharm. 6: 327-337
173. Lindstedt, S. L., Schaeffer, P. J. (2002) Use of allometry in predicting anatomical and physiological parameters of mammals. Lab. Animals 36: 1-19
174. Liu, L., Pang, K. S. (2005) The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. 33: 1-9
175. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 289: 1592-1599
176. Liu, X. D., Chen, J. (2001) Prediction of drug clearance in humans from laboratory animals based on body surface area. Eur. J. Drug Metab. Pharmacokinet. 26: 249-256
177. Lombardo, F., Gifford, E., Shalaeva, M. Y. (2003) In silico ADME prediction: data, models, facts and myths. Mini Rev. Med. Chem. 3: 861-875
178. Luttringer, O., Theil, F.-P., Poulin, P., Schmitt-Hoffmann, A. H., Guentert, T. W., Lavé, T. (2003) Physiologically based pharmacokinetic (PBPK) modelling of disposition of epiroprim in humans. J. Pharm. Sci. 92: 1990-2007
179. MacGregor, J. T., Collins, J. M., Sugiyama, Y., Tyson, C. A., Dean, J., Smith, L., Andersen, M. E., Curren, R. D., Houston, J. B., Kadlubar, F. F., Kedderis, G. L., Krishnan, K., Li, A. P., Parchment, R. E., Thummel, K., Tomaszewski, J. E., Ulrich, R., Vickers, A. E., Wrighton, S. A. (2001) In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 29: 17-36
180. Mahmood, I. (1997) Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: A critical review. Biopharm. Drug Dispos. 18: 465-473
181. Mahmood, I. (1998) Integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: some suggestions. J. Pharm. Sci. 87: 527-529
182. Mahmood, I. (1999) Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J. Pharm. Pharmacol. 51: 905-910
183. Mahmood, I. (2001) Interspecies scaling: is a priori knowledge of cytochrome P450 isozymes involved in drug metabolism helpful in prediction of clearance in humans from animal data? Drug Metab. Drug Interact. 18: 135-147
184. Mahmood, I. (2002a) Interspecies scaling: Predicting oral clearance in humans. Am. J. Ther. 9: 35-42
185. Mahmood, I. (2002b) Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metab. Drug Interact. 19: 49-64
186. Mahmood, I. (2004) Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J. Pharm. Sci. 93: 177-185
187. Mahmood, I. (2005) The correction factors do help in improving the prediction of human clearance from animal data. J. Pharm. Sci. 94: 940-947
188. Mahmood, I., Balian, J. D. (1996a) Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci. 85: 411-414
189. Mahmood, I., Balian, J. D. (1996b) Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci. 59: 579-585
190. Mahmood, I., Balian, J. D. (1996c) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26: 887-895
191. Mahmood, I., Balian, J. D. (1999) The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin. Pharmacokinet. 36: 1-11
192. Mahmood, I., Green, M. D., Fisher, J. E. (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J. Clin. Pharmacol. 43: 692-697
193. Masimirembwa, C. M., Bredberg, U., Andersson, T. B. (2003) Metabolic stability for drug discovery and development. Pharmacokinetic and biochemical challenges. Clin. Pharmacokinet. 42: 515-528
194. Matsui, K., Taniguchi, S., Yoshimura, T. (1999) Correlation of the clearance of donepezil (Aricept®) between in vivo and in vitro studies in rat, dog and human. Xenobiotica 29: 1059-1072
195. McGinnity, D. F., Soars, M. G, Urbanowicz, R. A., Riley, R. J. (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 32: 1247-1253
196. McMahon, T. A., Bonner, J. T. (1983) On size and life. Sci. Am. Lib. New York
197. Meier, P. J. Sztul, E. S., Reuben, A., Boyer, J. L. (1984) Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver. J. Cell Biol. 98: 991-1000
198. Mellet, L. B. (1969) Comparative drug metabolism. Prog. Drug Res. 13: 136-169
199. Mellick, G. D., Roberts, M. S. (1996) The disposition of aspirin and salicylic acid in the isolated perfused rat liver: The effect of normal and retrograde flow on availability and mean transit time. J. Pharm. Pharmacol. 48: 738-743
200. Mellick, G. D., Roberts, M. S. (1999) Structure-hepatic disposition relationships for phenolic compounds. Toxicol. Applied Pharmacol. 158: 50-60
201. Miyauchi, S., Sawada, Y., Iga, T., Hanano, M., Sugiyama, Y. (1993) Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm. Res. 10: 434-440
202. Mohutsky, M. A., Chien, J. Y., Ring, B. J., Wrighton, S. A. (2006) Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm. Res. 23: 654-662
203. Mordenti, J. (1985) Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J. Pharm. Sci. 74: 1097-1099
204. Mordenti, J. (1986) Man vs beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75: 1028-1040
205. Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B. L., Green, J. D. (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res. 8: 1351-1359
206. Mordenti, J., Osaka, G., Garcia, K., Thomsen, K., Licko, V., Meng, G. (1996) Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol. Appl. Pharmacol. 136: 75-78
207. Nagilla, R., Ward, K. W. (2004) A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J. Pharm. Sci. 93: 2522-2534
208. Naritomi, Y., Terashita, S., Kimura, S., Suzuki, A., Kagayama, A., Sugiyama, Y. (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29: 1316-1324
209. Naritomi, Y., Terashita, S., Kagayama, A., Sugiyama, Y. (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. 31: 580-588
210. Niro, R., Byers, J. P., Fournier, R. L., Bachmann, K. (2003) Application of a convective-dispersion model to predict in vivo hepatic clearance from in vitro measurements utilizing cryopreserved human hepatocytes. Curr. Drug Metab. 4: 357-369
211. Obach, R. S. (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27: 1350-1359
212. Obach, R. S. (2000) Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: Enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab. Dispos. 28: 1069-1076
213. Obach, R. S. (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr. Opin. Drug Disc. Develop. 4: 36-44
214. Obach, R. S., Reed-Hagen, A. E. (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab. Dispos. 30: 831-837
215. Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., MacIntyre, F., Ranee, D. J., Wastall, P. (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283: 46-58
216. Ott, P., Weisiger, R. A. (1999) Nontraditional effects of protein binding and hematocrit on uptake of indocyanine green by perfused rat liver. Am. J. Physiol. 273: G227-238
217. Ott, P., Bass, L., Keiding, S. (1997) Hepatic ICG removal in the pig depends on plasma protein and hematocrit: Evidence of sinusoidal binding disequilibrium and unstirred water layer effects. Hepatology 26: 679-690
218. Owens, S. M., Hardwick, W. C., Blackall, D. (1987) Phencyclidine pharmacokinetic scaling among species. J. Pharmacol. Exp. Ther. 242: 96-101
219. Pahlman, I., Kankaanranta, S., Palmer L. (2001) Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. Arzneimittelforschung 51: 134-144
220. Palm, K., Stenberg, P., Luthman, K., Artursson, P. (1997) Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14: 568-571
221. Pang, K. S., Rowland, M. (1977) Hepatic clearance of drugs I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5: 625-653
222. Pang, K. S., Barker, F., Simard, A., Schwab, A. J., Goresky, C. A. (1995) Sulphation of acetaminophen by the perfused rat liver: the effect of red blood cell carriage. Hepatology 22: 267-282
223. Pardridge, W. M., Sakiyama, R., Fierer, G. (1983) Transport of propranolol and lidocaine through the rat blood brain barrier. Primary role of globulin-bound drug. J. Clin. Invest. 71: 900-908
224. Paxton, J. W., Kim, S. N., Whitfield, L. R. (1990) Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res. 50: 2692-2697
225. Penzotti, J. E., Landrum, G. A., Putta, S. (2004) Building predictive ADMET models for early decisions in drug discovery. Curr. Opin. Drug Disc. Develop. 7: 49-61
226. Pérez, M. A. C., Snaz, M. B., Torres, L. R., Ávalos, R. G., González, M. P., Díaz, H. G. (2004) A topological sub-structural approach for predicting human intestinal absorption. Eur. J. Med. Chem. 39: 905-916
227. Peters, R. H. (1983) The ecological implications of body size. Cambridge University Press, Cambridge.
228. Piekoszewski, W., Chow, F. S., Jusko, W. J. (1993) Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. Drug Metab. Dispos. 21: 690-698
229. Plant, N. (2004) Strategies for using in vitro screens in drug metabolism. Drug Disc. Today 9: 328-336
230. Poggesi, I. (2004) Predicting human pharmacokinetics from preclinical data. Curr. Opin. Drug Disc. Develop. 7: 100-111
231. Pond, S. M., Tozer, T. N. (1984) First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. 9: 1-25
232. Proost, J. H., Nijssen, H. M. J., Strating, C. B., Meijer, D. K. F., Groothuis, G. M. M. (1993) Pharmacokinetic modeling of the sinusoidal efflux of anionic ligands from the isolated perfused rat liver: The influence of albumin. J. Pharmacokinet. Biopharm. 21: 375-394
233. Puigdemont, A., Guitart, R., Mora, F., Arboix, M. (1991) Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other species. J. Pharm. Sci. 80: 1106-1109
234. Railland, L., Guyomard, C., Scotte, M., Chesne, C., Guillouzo, A. (2000) Viability and drug metabolizing capacity of alginate-entrapped hepatocytes after cryopreservation. Cell Biol. Toxicol. 16: 105-116
235. Rane, A., Wilkinson, G. R., Shand, D. G. (1977) Prediction of hepatic extraction ratiofrom in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200: 420-424
236. Reinoso, R. F, Telfer, B. A., Brennan, B. S., Rowland, M. (2001) Uptake of teicoplanin by isolated rat hepatocytes: Comparison with in vivo hepatic distribution. Drug Metab. Dispos. 29: 453-459
237. Richter, W. F., Heizmann, P., Meyer, J., Starke, V., Lavé, T. (1998) Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J. Pharm. Sci. 87: 496-500
238. Riley, R. J., McGinnity, D. F., Austin, R. P. (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33: 1304-1311
239. Riond, J. L., Riviere, J. E. (1990) Allometric analysis of doxycycline pharmacokinetic parameters. J. Vet. Pharmacol. Ther. 13: 404-407
240. Ritschel, W. A., Vachharajani, N. N., Johnson, R. D., Hussain, A. S. (1992) The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. 103: 249-253
241. Roberts, S. A. (2001) High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31: 557-589
242. Roberts, M. S., Rowland, M. (1985) Hepatic elimination: The dispersion model. J. Pharm. Sci. 74: 585-587
243. Roberts, M. S., Rowland, M. (1986a) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14: 227-261
244. Roberts, M. S., Rowland, M. (1986b) A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J. Pharmacokinet. Biopharm. 14: 261-288
245. Roberts, M. S., Rowland, M. (1986c) A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J. Pharmacokinet. Biopharm. 14: 289-308
246. Roberts, M. S., Rowland, M. (1986d) Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J. Pharm. Pharmacol. 38: 177-181
247. Roberts, M. S., Fraser, S., Wagner, A., McLeod, L. (1990) Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate. J. Pharmacokinet. Biopharm. 18: 209-234
248. Rowland, M. (1984) Protein binding and drug clearance. Clin. Pharmacokinet. 9(Suppl. 1): 10-17
249. Rowland, M., Tozer, T. N. (1995) In: Rowland, M., Tozer, T. N. (eds). Clinical pharmacokinetics: concepts and applications. Williams & Wilkins, Baltimore, MD
250. Rowland, M., Benet, L. Z., Graham, G. G. (1973) Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1: 123-136
251. Rubner, N. (1883) Ueber den einfluss der koepergrosse auf stoff und kraftwechsel. Z. Biol. 19: 535-562
252. Sahin, S., Rowland, M. (2004) Effect of erythrocytes on the hepatic distribution kinetics of antipyrine. Eur. J. Drug Metab. Pharmacokinet. 29: 37-41
253. Sanwald-Ducray, P., Dow, J. (1997) Prediction of the pharmacokinetic parameters of reduced dolasteron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 27: 189-201
254. Saville, B. A., Gray, M. R., Tam, Y. K. (1992a) Models of hepatic drug elimination. Drug Metab. Rev. 24: 49-88
255. Saville, B. A., Gray, M. R., Tam, Y. K. (1992b) Experimental studies of transient mass transfer and reaction in the liver: Interpretation with a heterogenous compartment model. J. Pharm. Sci. 81: 265-271
256. Sawada, Y., Hanano, M. Sugiyama, Y., Harashima, H., Iga, T. (1984) Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J. Pharmacokinet. Biopharm. 12: 587-596
257. Sawada, Y., Hanano, M., Sugiyama, Y., Iga T. (1985) Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J. Pharmacokinet. Biopharm. 13: 477-492
258. Schmidt-Nielsen, K. (1984) Why is animal size so important! Cambridge University Press, Cambridge
259. Schneider, G., Coassolo, P., Lavé, T. (1999) Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J. Med. Chem. 42: 5072-5076
260. Schwab, A. J., Barker III, F., Goresky, C. A., Pang, K. S. (1990) Transfer of enalaprilat across rat liver cell membranes is barrier limited. Am. J. Physiol. 258: G461-475
261. Schwarz, L. R., Schwenk, M., Barth, C., Greim, H. (1979) Studies with isolated liver cells: Effect of taurolithocholate on the transport of taurocholate and bromosulfophtalein. In: Paumgartner, G., Stiel, D. (eds) Biological effects of bile acids. MTP Press, Lancaster, pp 127-133
262. Schwenk, M. (1980) Transport systems of isolated hepatocytes: Studies on the transport of biliary compounds. Arch. Toxicol. 44: 113-126
263. Shand, D. G., Branch, R. A., Evans, G. H., Nies, A. S., Wilkonson, G. R. (1973) The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver. Drug Metab. Dispos. 1: 679-686
264. Shibata, Y., Takahashi, H., Ishii, Y. (2000) A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos. 28: 1518-1523
265. Shibata, Y., Takahashi, H., Chiba, M., Ishii, Y. (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos. 30: 892-896
266. Shim, H. J., Kim, Y. C., Lee, J. H., Kwon, J. W., Kim, W. B., Kim, Y. G., Kim, S. H., Lee, M. G. (2005) Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Disp. 26: 269-277
267. Siebert, G. A., Hung, D. Y., Chang, P., Roberts, M. S. (2004) Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J. Pharmacol. Exp. Ther. 308: 228-235
268. Sietsema, W. K. (1989) The absolute oral bioavailability of selected drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 27: 179-211
269. Simeonova, M., Wachner, D., Gimsa, J. (2002) Cellular absorption of electric filed energy: influence of molecular properties of the cytoplasm. Bioelectrochemistry 56: 215-218
270. Singh, K., Tripp, S. L., Dunton, A. W., Douglas, F. L., Rakhit, A. (1991) Determination of in vivo hepatic extraction ratio from in vitro metabolism by rat hepatocytes. Drug Metab. Dispos. 19: 990-996
271. Skett, P. (1994) Problems in using isolated and cultured hepatocytes for xenobiotic metabolism/metabolism-based toxicity testing-solutions. Toxicol. In Vitro 8: 491-504
272. Soars, M. G., Burchell, B., Riley, R. J. (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. Pharmacol. Exp. Ther. 301: 382-390
273. Sohlenius-Sternbeck, A.-K., Schmidt, S. (2005) Impaired glutathione-conjugating capacity by cryopreserved human and rat hepatocytes. Xenobiotica 35: 727-736
274. Steinberg, P., Fischer, T., Kiulies, S., Biefang, K., Piatt, K. L., Oesch, F., Bottger, T., Bulitta, C., Kempf, P., Hengstler, J. (1999) Drug metabolizing capacity of cryopreserved human, rat and mouse liver parenchymal cells in suspension. Drug Metab. Dispos. 27: 1415-1422
275. St-Pierre, M. V., Lee, P. I., Pang, K. S. (1992) A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination. J. Pharmacokinet. Biopharm. 20: 105-145
276. Swabb, E. A., Bonner, D. P. (1983) Prediction of aztreonam pharmacokinetics in humans based on data from animals. J. Pharmacokinet. Biopharm. 11: 215-223
277. Tang, H., Mayersohn, M. (2005) A novel model for prediction of human drug clearance by allometric scaling. Drug Metab. Dispos. 33: 1297-1303
278. Tang, H., Mayersohn, M. (2006a) On the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: Further support for a proposed model based on plasma protein binding. J. Clin. Pharmacol. 46: 398-400
279. Tang, H., Mayersohn, M. (2006b) A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J. Pharm. Sci. 95: 1783-1799
280. 1B receptor antagonist: pharmacokinetic scaling studies. Eur. Neuropsychopharmacol. 3: 213
281. Thummel, K. E., Kunze, K. L., Shen, D. D. (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Del. Rev. 27: 99-127
282. Travis, C. C., White, R. K., Ward, R. C. (1990) Interspecies extrapolation of pharmacokinetics. J. Theor. Biol. 142: 285-304
283. Treijtel, N., Barendregt, A., Freidig, A. P., Blaauboer, B. J., van Eijkeren, J. C. H. (2004) Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutaminde determined in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 32: 884-891
284. Tucker, G. T., Houston, J. B., Huang, S.-M. (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential: toward a consensus. Pharm. Res. 18: 1071-1080
285. Ubeaud, G., Schmitt, C., Jaeck, D., Lavé, T., Coassolo, P. (1995) Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25: 1381-1390
286. van de Waterbeemd, H., Gifford, E. (2003) ADMET in silico modeling: Towards prediction paradise? Nature Rev. Drug Disc. 2: 192-204
287. van Eijkeren, J. C. (2002) Estimation of metabolic rate constants in PBPK-models from liver slice experiments: What are the experimental needs? Risk Anal. 22: 159-173
288. van Hoogdalem, E. J., Soeishi, Y., Matsushima, H., Higuchi S. (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J. Pharm. Sci. 86: 1156-1161
289. Videla, L., Flattery, K. V., Sellers, E. A., Israel, Y. (1975) Ethanol metabolism and liver oxidative capacity in cold acclimation. J. Pharmacol. Exp. Ther. 192: 575-582
290. von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., Dent, J., Somogyi, A. A., Eichelbaum, M. (2001) Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin. Pharmacol. Ther. 70: 217-227
291. Wajima, T., Fukumura, K., Yano, Y., Oguma, T. (2002) Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J. Pharm. Sci. 91: 2489-2499
292. Wajima, T., Fukumura, K., Yano, Y., Oguma, T. (2003) Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: Oral clearance. J. Pharm. Sci. 92: 2427-2440
293. Wajima, T., Yano, Y., Fukumura, K., Oguma, T. (2004) Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J. Pharm. Sci. 93: 1890-1900
294. Walker, C. H. (1978) Species differences in microsomal monooxygenase activity and the relationship of biological half-lives. Drug Met. Rev. 7: 295-323
295. Ward, K. W., Smith, B. R. (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab. Dispos. 32: 603-611
296. Ward, K. W., Azzarano, L. M., Bondinell, W. E., Cousins, R. D., Huffman, W. F., Lakas, D. R., Keenan, R. M., Ku, T. W., Lundberg, D., Miller, W. H., Mumaw, J. A., Newlander, K. A., Pirhalla, J. L., Roethke, T. J., Salyers, K. L., Souder, P. R., Stelman, G. J., Smith, B. J. (1999) Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab. Dispos. 27: 1232-1241
297. Ward, K. W., Proksch, J. W., Gorycki, P. D., Yu, C.-P., Ho, M. Y. K., Bush, B. D., Levy, M. A., Smith, B. R. (2002) SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man. Xenobiotica 32: 235-250
298. Weibel, E. R., Staubli, W., Gnagi, H. R., Hess, F. A. (1969) Correlated morphometric and biochemical studies on the liver cell. Morphometric model, and normal morphometric data for rat liver. J. Cell Biol. 42: 68-91
299. Weisiger, R. A. (1985) Dissociation from albumin: A potentially rate-limiting step in the clearance of substrates by the liver. Proc. Natl. Acad. Sci. USA 82: 1563-1567
300. Weisiger, R. A., Pond, S., Bass, L. (1991) Hepatic uptake of protein-bound ligands: Extended sinusoidal perfusion model. Am. J. Physiol. 261: G872-884
301. Weiss, M., Sziegoleit, W., Forster, W. (1977) Dependence of pharmacokinetic parameters on the body weight. Int. J. Clin. Pharmacol. Biopharm. 15: 572-575
302. Weiss, T. S., Jahn, B., Cetto, M., Jauch, K.-W., Thasler, W. E. (2002) Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif. 35: 257-267
303. Wessel, M. D., Jurs, P. C., Tolan, J. W., Muskal, S. M. (1998) Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comp. Sci. 38: 726-735
304. West, G. B., Brown, J. H., Enquist, B. J. (1997) A general model for the origin of allometric scaling laws in biology. Science 276: 122-126
305. Wilkinson, G. R., Shand, D. G. (1975) Commentary - A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18: 377-390
306. Winkler, K., Bass, L., Keiding, S., Tygstrup, N. (1974) The effect of hepatic perfusion on the assessment of kinetic constants in regulation of hepatic metabolism. In: Lundquist, F., Tygstrup, N. (eds) A Benzon Symposium VI. Munksgaard, Copenhagen, pp 797-807
307. Worboys, P. D., Bradbury, A., Houston, J. B. (1995) Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. Drug Metab. Dispos. 23: 393-397
308. Worboys, P. D., Bradbury, A., Houston, J. B. (1996a) Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab. Dispos. 24: 676-681
309. Worboys, P. D., Bradbury, A., Houston, J. B. (1996b) Kinetics of drug metabolism in rat liver slices. III. Relations between metabolic clearance and slice uptake rate. Drug Metab. Dispos. 24: 460-467
310. Worboys, P. D., Brennan, B., Bradbury, A., Houston, J. B. (1997) Metabolic kinetics of ondansetron in rat. Comparisons of hepatic microsomes, isolated hepatocytes and liver slices with in vivo disposition. Xenobiotica 26: 897-907
311. Wortelboer, H. M., De Kruif, C. A., van Iersel, A. A. J, Falke, H. E., Noordhoek, J., Blaauboer, B. J. (1990) The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochem. Pharmacol. 40: 2525-2534
312. Xu, X., Schwab, A. J., Barker III, F., Goresky, C. A., Pang, K. S. (1994) Salicylamide sulphate cell entry in perfused rat liver: A multiple-indicator dilution study. Hepatology 19: 229-244
313. Yamasaki, S., Toth, L. N., Black, M. L., Duncan, J. N. (2004) Comparison of prediction methods for in vivo clearance of (S, S)-3-[3-(methylsulfonyl) phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. Drug Metab. Dispos. 32: 398-404
314. Yates, F. E., Kugler, P. N. (1986) Similarity principles and intrinsic geometries: Contrasting approaches to interspecies scaling. J. Pharm. Sci. 75: 1019-1027
315. Zomorodi, K., Carlile, D.J., Houston, J. B. (1995) Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 25: 907-916
316. Zuegge, J., Schneider, G., Coassolo, P., Lavé, T. (2001) Prediction of hepatic metabolic clearance. Clin. Pharmacokinet. 40: 553-563